Liver Disease

News

FDA approves lenvatinib for HCC

Lenvatinib was found noninferior but not statistically superior to sorafenib for overall survival in a trial of 954 patients.

Conference Coverage

Hot topics

Hepatitis B virus reactivation, endoscopic bariatric therapy, and more.

Pages